Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Gears Up For Phase-2 Clinical Trials Of Ralinepag

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued a press release stating that the enrollment of the ralinepag phase-2 clinical trials, is now closed, with 60 patients enrolled worldwide. It should be noted here that the drug has been developed as a treatment for pulmonary arterial hypertension. The announcement also revealed that the trial would be carried out […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Receives FDA’s Approval Of BELVIX XR CIV.

The approval of a weight-loss drug from Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) by the FDA was a plus for the company’s shares. The approval of the New Drug Application (NDA) for BELVIX XR CIV extended release 20 mg tablets is another milestone for the company as expressed by Arena’s CEO Amit Munshi, which shows its commitment to […]

Orexigen Therapeutics, Inc. (NASDAQ:OREX)’s Long-Awaited Obesity Pill Contrave Received FDA Nod

Boston, MA 09/12/2014 (wallstreetpr) – The U.S. Food and Drug Administration gave a green signal to Orexigen Therapeutics, Inc. (NASDAQ:OREX) diet pill called Contrave for sale in the country. The reason why this approval holds prominence is because it is the only third kind of obesity treatment/pill in over 10 years, which has received FDA’s […]

Why Orexigen Therapeutics, Inc. (NASDAQ:OREX) May Ride Smooth In Tricky Weight-Drug Market

Boston, MA 06/11/2014 (wallstreetpr) – Orexigen Therapeutics, Inc. (NASDAQ:OREX) intends to bring its obesity drug called Contrave to the market after the U.S. Food and Drug Administration issues its verdict today. The approval of the drug will be a milestone for the company given its many past challenges to bring the drug to the market. […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Will Be Announcing 3Q13 Earnings On November 7, 2013

Boston, MA 11/01/2013 (wallstreetpr) – The stock of San Diego, California based Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shed 3.11% of its market cap to $951.59 million and end the session at $4.36, about 3.81% above its 52 week low of $4.20 hit on Oct 11, 2013. The stock traded with volume of 6.58 million shares against its 30 […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Sales Force To Sell Belviq Doubled

Boston, MA 10/17/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) recently announced that their partner Eisai Inc is all set to increase the size of sales force that is involved in selling Belviq, their weight management drug by two times. Ever since the launch of the drug, it has turned out to be successful and there has […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Plans To Double The Sales Force Involved With Anti-Obesity Drug Belviq

Boston, MA 10/16/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released a report on October 15, and according to the report Eisai Inc. would be increasing the number of sales staff involved with the sales of the anti-obesity drug Belviq. As per the report the sales force number would touch 400 by the month of December this […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Withdrew Application Of Market Diet Drug

Boston, MA 10/10/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) filed an application seeking marketing rights of its drug. The drug is an anti-obesity drug and helps people to lose weight. Now, the company has withdrawn its application, post which the stock prices of the company fell by 15 percent. The European Medicines Agency’s committee said that […]

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Gains When People Lose Weight

Boston, MA 10/01/2013 (wallstreetpr) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had launched the anti-obesity drug Belviq about three months back. It is the first drug, in a period of 13 years, to be permitted by the Food and Drug Administration for this purpose. In these three months, impressive results of the drug have been reported. Patients who […]